NASDAQ
Immuneering Corporation (IMRX) has a free cash flow growth of -85.79% as of Friday, May 29, 2026. This represents a 1424.15% decrease compared to its 12-month average of 6.48%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.